Use of chimeric antigen receptor-modified T cells to treat cancer
US9328156B2 · kind B2 · utility
78Cited by
27References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 16, 2013 |
| Grant date | May 3, 2016 |
| Priority date | — |
| Expiry date | Dec 16, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/15071
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.